The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

Ozempic maker Novo Nordisk (NVO) shared more details about its experimental anti-obesity pill — that seems to be more ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...